The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge

• 来源期刊: 科学通报（英文版）
• 年，卷（期）: 2019,（8）
• 页码范围: 499-503
• 页数: 5页
• 语种: 英文

摘要

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated impressive activity in EGFR T790M-positive non-small cell lung cancer (NSCLC) progressed from prior EGFR-TKIs [1,2]. However, resistance inevitably occurred after approximately 10 months of treatment. EGFR C797S mutation has been reported as one of the major resistance mechanisms to osimertinib, occurring in around 14％–24％ of patients progressed from osimertinib [3,4]. Till now, multiple studies have focused on the onset of EGFR C797S in this subset of patients. Little is known about the spatiotemporal evolution of EGFR C797S mutation during subsequent treatment course. Here we present four cases showing the spatiotemporal evolution of EGFR C797S during subsequent treatment after progression from third-generation EGFR-TKI AC0010 (Abivertinib), which is a pyrrolopyrimidinebased, irreversible, EGFR-TKI, structurally distinct from pyrimidine-based osimertinib and rociletinib [5].